Quick Answer
Tempest Therapeutics, Inc. reported Research And Development Expense of $18.34 million for the year ending 2017.
- Tempest Therapeutics, Inc. showed a decrease of -15.3% in Research And Development Expense from 2016 to 2017.
- This data is from Tempest Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 15, 2018.
- XBRL data for this metric is available from 2012 to 2017 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: $404.0 thousand | Q2 2012: $1.35 million | Q3 2012: $1.60 million | Q1 2013: $2.68 million | Q2 2013: $2.58 million | Q3 2013: $3.26 million | Q1 2014: $4.65 million | Q2 2014: $4.53 million | Q3 2014: $5.33 million | Q1 2015: $5.75 million | Q2 2015: $4.02 million | Q3 2015: $4.00 million | Q1 2016: $5.96 million | Q2 2016: $5.99 million | Q3 2016: $4.99 million | Q1 2017: $5.76 million | Q2 2017: $5.00 million | Q3 2017: $4.02 million | Q1 2018: $2.62 million | Q2 2018: $2.39 million | Q3 2018: $1.68 million.
- Over the full 6 years of available data (2012 to 2017), Tempest Therapeutics, Inc.'s Research And Development Expense has grown by 190.0%.
- Historical annual values: Fiscal year 2017: $18.34 million | Fiscal year 2016: $21.64 million | Fiscal year 2015: $18.43 million | Fiscal year 2014: $21.78 million | Fiscal year 2013: $15.80 million | Fiscal year 2012: $6.32 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: